CO2023016072A2 - Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar - Google Patents
Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliarInfo
- Publication number
- CO2023016072A2 CO2023016072A2 CONC2023/0016072A CO2023016072A CO2023016072A2 CO 2023016072 A2 CO2023016072 A2 CO 2023016072A2 CO 2023016072 A CO2023016072 A CO 2023016072A CO 2023016072 A2 CO2023016072 A2 CO 2023016072A2
- Authority
- CO
- Colombia
- Prior art keywords
- bile acid
- compounds
- benzothia
- acid modulators
- diseases
- Prior art date
Links
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract 3
- 239000003613 bile acid Substances 0.000 title abstract 3
- 150000001538 azepines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 abstract 2
- 108091006614 SLC10A2 Proteins 0.000 abstract 2
- CICPSCXBPAGDJY-UHFFFAOYSA-N 1,2,5-benzothiadiazepine Chemical class S1N=CC=NC2=CC=CC=C12 CICPSCXBPAGDJY-UHFFFAOYSA-N 0.000 abstract 1
- KJFRSZASZNLCDF-UHFFFAOYSA-N 1,5-benzothiazepine Chemical compound S1C=CC=NC2=CC=CC=C12 KJFRSZASZNLCDF-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004129 fatty acid metabolism Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La invención se refiere a los derivados de 1,5-benzotiazepina y 1,2,5-benzotiadiazepina de la fórmula (I). Estos compuestos son moduladores del ácido biliar que tienen el transportador apical del ácido biliar dependiente del sodio (ASBT) y/o actividad inhibidora del transporte del ácido biliar del hígado (LBAT). La invención también se refiere a las composiciones farmacéuticas que comprenden estos compuestos y con el uso de estos compuestos en el tratamiento de enfermedades cardiovasculares, metabolismo del ácido graso y trastornos debido al uso de la glucosa, enfermedades gastrointestinales y enfermedades hepáticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202111024711 | 2021-06-03 | ||
| PCT/EP2022/065165 WO2022253997A1 (en) | 2021-06-03 | 2022-06-03 | Benzothia(di)azepine compounds and their use as bile acid modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023016072A2 true CO2023016072A2 (es) | 2023-12-11 |
Family
ID=82156361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0016072A CO2023016072A2 (es) | 2021-06-03 | 2023-11-23 | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220402885A1 (es) |
| EP (1) | EP4347575A1 (es) |
| KR (1) | KR20240017844A (es) |
| CN (1) | CN117412955A (es) |
| AR (1) | AR126076A1 (es) |
| AU (1) | AU2022285893A1 (es) |
| BR (1) | BR112023024850A2 (es) |
| CA (1) | CA3218474A1 (es) |
| CO (1) | CO2023016072A2 (es) |
| IL (1) | IL308582A (es) |
| TW (1) | TW202313579A (es) |
| WO (1) | WO2022253997A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220082931A (ko) | 2014-06-25 | 2022-06-17 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| PE20210182A1 (es) | 2018-06-20 | 2021-01-29 | Albireo Ab | Modificaciones de cristales de odexibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| KR20220109450A (ko) | 2019-12-04 | 2022-08-04 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도 |
| CN114761080A (zh) | 2019-12-04 | 2022-07-15 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| WO2023203248A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
| WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59108326D1 (de) | 1990-12-06 | 1996-12-12 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel |
| FI108451B (fi) | 1991-12-20 | 2002-01-31 | Hoechst Ag | Menetelmõ polymeeristen ja oligomeeristen sappihappojohdannaisten valmistamiseksi |
| GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| DK0573848T3 (da) | 1992-06-12 | 1998-08-10 | Hoechst Ag | Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler |
| IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| TW289021B (es) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
| TW289757B (es) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
| TW289020B (es) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
| ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| AU700557B2 (en) | 1994-09-13 | 1999-01-07 | Monsanto Company | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
| EP0864582B1 (en) | 1997-03-14 | 2003-06-04 | Aventis Pharma Deutschland GmbH | Hypolipidemic 1,4-benzothiazepine-1,-dioxides |
| DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| ATE349214T1 (de) | 2001-09-08 | 2007-01-15 | Astrazeneca Ab | Benzothiazepin und benzothiadiazepin derivative mit hemmender wirkung auf den säuretransport in den gallengängen zur behandlung von hyperlipidaemia |
| GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
| ATE531701T1 (de) | 2002-08-28 | 2011-11-15 | Asahi Kasei Pharma Corp | Neue quaternüre ammoniumverbindungen |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| US20050215882A1 (en) | 2004-03-23 | 2005-09-29 | The Regents Of The University Of Michigan | Noninvasive method to determine fat content of tissues using MRI |
| DE102005033100B3 (de) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
| DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
| US9295677B2 (en) | 2008-02-26 | 2016-03-29 | Qing Bile Therapeutics Inc. | Polyhydroxylated bile acids for treatment of biliary disorders |
| JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
| AU2012328453B2 (en) * | 2011-10-28 | 2017-05-04 | Shire Human Genetic Therapies, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| SG11201607075TA (en) | 2014-02-27 | 2016-09-29 | Nusirt Sciences Inc | Compositions and methods for the reduction or prevention of hepatic steatosis |
| KR101674806B1 (ko) | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
| KR20160061492A (ko) | 2014-11-21 | 2016-06-01 | 삼성디스플레이 주식회사 | 휴대용 먼지 센서 및 이를 이용한 휴대전화 |
| CA3011565C (en) | 2016-02-09 | 2024-01-02 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| RU2750937C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
| US11350844B2 (en) | 2016-11-23 | 2022-06-07 | Mayo Foundation For Medical Education And Research | System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography |
| CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| WO2019032027A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
| US10975045B2 (en) * | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) * | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| TW202134218A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其作為膽酸調節劑之用途 |
| WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| AR120679A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
| TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
-
2022
- 2022-06-02 TW TW111120675A patent/TW202313579A/zh unknown
- 2022-06-03 EP EP22732489.4A patent/EP4347575A1/en active Pending
- 2022-06-03 AU AU2022285893A patent/AU2022285893A1/en active Pending
- 2022-06-03 IL IL308582A patent/IL308582A/en unknown
- 2022-06-03 KR KR1020237043618A patent/KR20240017844A/ko unknown
- 2022-06-03 AR ARP220101481A patent/AR126076A1/es unknown
- 2022-06-03 CN CN202280038820.2A patent/CN117412955A/zh active Pending
- 2022-06-03 CA CA3218474A patent/CA3218474A1/en active Pending
- 2022-06-03 BR BR112023024850A patent/BR112023024850A2/pt unknown
- 2022-06-03 WO PCT/EP2022/065165 patent/WO2022253997A1/en active Application Filing
- 2022-07-18 US US17/813,152 patent/US20220402885A1/en active Pending
-
2023
- 2023-11-23 CO CONC2023/0016072A patent/CO2023016072A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220402885A1 (en) | 2022-12-22 |
| CA3218474A1 (en) | 2022-12-08 |
| BR112023024850A2 (pt) | 2024-02-20 |
| EP4347575A1 (en) | 2024-04-10 |
| CN117412955A (zh) | 2024-01-16 |
| AU2022285893A9 (en) | 2023-11-30 |
| KR20240017844A (ko) | 2024-02-08 |
| WO2022253997A1 (en) | 2022-12-08 |
| TW202313579A (zh) | 2023-04-01 |
| AU2022285893A1 (en) | 2023-11-23 |
| AR126076A1 (es) | 2023-09-06 |
| IL308582A (en) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001934A1 (es) | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar. | |
| CO2022007172A2 (es) | Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar | |
| CL2022001453A1 (es) | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar | |
| CO2023016072A2 (es) | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar | |
| AR120676A1 (es) | Compuestos de benzoti(di)azepina y su uso como ácido biliar | |
| BR112023010799A2 (pt) | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares | |
| ECSP11011324A (es) | 3h-imidazo[4,5-c]piridina-6-carboxamidas en calidad de agentes antiinflamatorios | |
| AR120674A1 (es) | Compuestos de benzotiazepina y su uso como ácido biliar | |
| UY27846A1 (es) | Compuestos quimicos | |
| EA201270666A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
| EA201001532A1 (ru) | Соединения фенилзамещенного 2-имино-3-метилпирролопиримидинона в качестве ингибиторов bace-1, композиции и их применение | |
| UY29412A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. | |
| AR072233A1 (es) | Derivados de acido lipoico y composiciones farmaceuticas que los contienen y metodos para tratar una enfermedad | |
| GT200500026A (es) | Derivados de beta-aminoacidos como inhibidores del factor xa. | |
| CL2004000590A1 (es) | Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v | |
| GT201100336A (es) | Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas | |
| CO2022011728A2 (es) | Composiciones y usos de glp-1 | |
| DK1502586T3 (da) | Anvendelse af desinficerende midler ved fremstillingen af en farmaceutisk sammensætning til forebyggelsen eller behandlingen af inflammationer i det indre af menneskekroppen | |
| ECSP034470A (es) | 6.alfa.,9.alfa-difluor-17.alfa.- (2-furanilcarboxilo) oxy-11.beta.-hidroxi-16.alfa.-metil-3-oxo-androst-1,4,-diene-17-acido carbotiotico s-fluormetil ester como un agente anti-inflamatorio | |
| KR101480280B1 (ko) | 타우로우루소데옥시콜릭산을 포함하는 조성물 | |
| GT200600274A (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado y su uso como agentes farmacétuicos | |
| AR029629A1 (es) | Cefaiboles, nuevos antiparasitos obtenidos a partir de acremonium tubaki, procedimiento para su preparacion composiciones farmaceuticas y procedimiento para su preparacion y utilizacion de los mismos para preparar un medicamento. | |
| BR0008368A (pt) | Derivados fenilalaninol | |
| PA8444901A1 (es) | Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios | |
| MA56430B1 (fr) | Composés de benzothiadiazépine et leur utilisation en tant que modulateurs d'acide biliaire |